Shares of Prothena Corp. rallied in the extended session Thursday after the biotech said an early-stage study showed its Parkinson's drug candidate lowered levels of a protein associated with the disease. Prothena shares jumped 38% to $40.20 on moderate volume. The company said the drug PRX002 lowered levels of free serum alpha-synuclein up to 96% in Parkinson's patients. Alpha-synuclein is potentially involved in the onset and progression of Parkinson's, the company said.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below